Mice transplanted with Dnmt3a-KO HSCs have reduced survival. (A) WBC and lymphocyte (LY) count at 26 weeks posttransplant; n = 18 WT and n = 41 Dnmt3a-KO. Error bars represent mean plus standard deviation. (B) Kaplan-Meier survival curve of mice transplanted with WT (n = 20) or Dnmt3a-KO (n = 45) HSCs. Censored points (squares) represent 5 mice that were sacrificed for a nonhematopoietic phenotype. Median survival is 321 days for Dnmt3a-KO; undetermined for WT. The experiment was repeated with the same numbers of animals, with median survival times of 246 days for mice transplanted with Dnmt3a-KO HSCs and 467 days for those transplanted with WT. (C) Number of mice in the transplanted cohort that were definitively diagnosed with the indicated hematopoietic diseases. ***P < .0001. B-ALL, B-cell acute lymphocytic leukemia/lymphoma; CMML, chronic myelomonocytic leukemia; ETP, early thymic progenitor acute lymphoblastic leukemia; PMF, primary myelofibrosis.